MannKind Provides Regulatory Update

VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) today announced that it was informed by the U.S. Food & Drug Administration (FDA) that due to a potential government shutdown the FDA has decided to cancel an End-of-Review meeting with MannKind that was to be held on April 15, 2011. The FDA stated that when it is able to do so it will reschedule the meeting to the next possible date. MannKind will provide a further update about its planned interactions with the FDA at its first quarter analyst call on April 25, 2011.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind is also evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a phase 2 clinical trial. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

CONTACT

MannKind Corporation Matthew Pfeffer Chief Financial Officer 661-775-5300 [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Research Diabetes FDA Science General Health

MEDIA:

Logo